“Emirates for the drug” adopts the first oral medicine to treat multiple progressive secondary sclerosis

The Emirates Drug Corporation announced the adoption of “Tolbrotinib” as the first global oral medicine to treat multiple, non -dependent secondary sclerosis, in an achievement that reflects the leadership of the UAE in accelerating the availability of innovative treatments.

The achievement reflects the state’s commitment to providing advanced therapeutic solutions based on the latest findings of the flag, in order to enhance the quality of patients ’life and keep pace with global health care developments.

The property was approved, based on a scientific study conducted in cooperation with the National Association for Multiple Sclerosis, where “Tolbrotinip” is the only treatment that directly targets the accumulation of disability regardless of the setbacks, within the framework of supporting organizational decisions based on evidence, and enhancing the quality of health care for multiple sclerosis patients in the UAE.

Tolbrotinip was developed as an oral inhibitor targeting specific immune cells within the central nervous system, which are bi -cells and small glial cells, which are believed to play a major role in the progress of the disease, and by targeting chronic underlying nervous inflammation, the drug provides a new treatment approach to address the radical cause of the accumulation of disability independently of relapses, which was not achieved by previous treatments.

Dr. Fatima Al -Kaabi, Director General of the Foundation, stressed that this accreditation reflects the success of the UAE’s pre -emptive policies in developing a flexible organizational environment that supports innovation, and accelerates patients’ access to advanced treatments.

She said that the adoption of Tolbrotinib is a qualitative shift in the face of one of the most complex neurological diseases, and embodies the Foundation’s commitment to accelerate the availability of innovative treatments that make a real difference in the lives of patients, noting that the Foundation is keen to adopt a pre -emptive approach based on innovation and global partnerships, in order to ensure the provision of effective and safe treatment options according to the highest international standards.

“This dependence represents the result of complementary efforts between the institution and its international partners in supporting scientific innovation and its practical application to serve patients, and we at the institution believe in the importance of accelerating organizational measures in areas that witness a great medical need, and this achievement comes to confirm the readiness of the health system in the state to keep pace with accelerated scientific developments, and to provide quality treatments that contribute to improving the quality of life and promoting health security National.

The partnership with the National Society for Multiple Sclerosis represents a milestone in the path of developing treatments directed to the multi -progressive sclerosis patients, as this cooperation resulted in the adoption of the first treatment that directly targeting mechanisms of providing disability away from setbacks, and that the adoption of this advanced scientific orientation and effective partnership reflects the leadership of the UAE in accelerating access to scientific innovations, and the Emirates Foundation’s commitment to improve the quality of patients ’life, and enhances access to existing treatments On well -established scientific evidence.